Chemical produced in pancreas that prevented and reversed Type 1 diabetes in mice had the same effect on human beta cells transplanted into mice
A chemical produced in the pancreas that prevented and even reversed Type 1 diabetes in mice had the same effect on human beta cells transplanted into mice, new research has found.
A chemical produced in the pancreas that prevented and even reversed Type 1 diabetes in mice had the same effect on human beta cells transplanted into mice, according to a paper in the Dec. issue of Diabetes by Dr. Gerald Prud'homme (left) and Qinghua Wang (right) of the Keenan Research Centre for Biomedical Sciences of St. Michael's Hospital in Toronto.
Credit: Courtesy of St. Michael's Hospital
GABA, or gamma-aminobutryic acid, is an amino acid produced by the same beta cells that make and secrete insulin.
Drs. Gerald Prud'homme and Qinghua Wang of the Keenan Research Centre for Biomedical Sciences of St. Michael's Hospital published a paper in 2011 showing for the first time that GABA injections not only prevented Type 1 diabetes in mice, but even reversed the disease.
A new paper published (Nov. 29) in the December issue of Diabetes shows GABA does the same thing in mice who have been injected with human pancreatic cells.
Type 1 diabetes, formerly known as juvenile diabetes, is characterized by the immune system's destruction of the beta cells in the pancreas. As a result, the body makes little or no insulin. The only conventional treatment for Type 1 diabetes is insulin injection, but insulin is not a cure as it does not prevent or reverse the loss of beta cells.
Drs. Prud'homme and Wang also found that GABA vastly improved the survival rate of pancreatic cells when they were being transplanted into mice. About 70 per cent of pancreatic cells die between the time the organ is harvested and transplanted. The researchers said their finding could lead to future research specifically related to pancreatic transplants.
GABA has been known for decades to be a key neurotransmitter in the brain, a chemical that nerve cells use to communicate with each other, but its role in the pancreas was unknown until the 2011 paper by Drs. Prud'homme and Wang.
GABA and related therapies would have to be tested in human clinical trials, a process that could take several years, the researchers said, noting that many treatments that work in mice do not always translate into effective human therapies.
This study received funding from the Juvenile Diabetes Research Foundation and the Canadian Institutes for Health Research.
About St. Michael's Hospital
St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 23 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, and care of the homeless are among the Hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Centre, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.
For more information, or to speak to Drs. Prud'homme or Wang, please contact Leslie Shepherd, Manager of Media Strategy.
Inspired Care. Inspiring Science.
Follow us on Twitter: http://www.twitter.com/stmikeshospital
Leslie Shepherd | EurekAlert!
A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich
New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
17.02.2017 | Medical Engineering
17.02.2017 | Medical Engineering
17.02.2017 | Health and Medicine